Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OmaMig Pilot
2025-522448-41-00Phase 2Authorised
- Sponsor
- Oslo University Hospital
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of omalizumab in episodic migraine, sponsored by Oslo University Hospital. Planned start Mar 2026; status: authorised.
02
Drugs
omalizumab
03
Conditions
episodic migraine
Beyond the preview
Go deeper on 2025-522448-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522448-41-00.